Blastogenic responses of human lymphocytes to a streptococcal preparation OK-432 and its fractions. 1989

T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
3rd Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.

This study was undertaken to examine the blastogenic responses of PBL to Streptococcal preparation OK-432 and its fractions. The results showed that OK-432 and its fractions, Su-PR and PM, have the mitogenic activity against human lymphocytes. The demonstration that PBL which had been cultured with OK-432 expressed IL-2 receptors and the blastogenic responses of PBL to OK-432 were inhibited by anti-IL-2 antibody suggested that IL-2 and IL-2 receptors might play a central role in OK-432-induced proliferation of human lymphocytes.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
March 1989, Journal of clinical & laboratory immunology,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
July 1989, Cancer,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
January 1987, International journal of immunopharmacology,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
September 1987, The Tokai journal of experimental and clinical medicine,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
April 2005, The Journal of dermatological treatment,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
January 1984, International archives of allergy and applied immunology,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
April 1988, Journal of biological response modifiers,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
June 1983, Hiroshima journal of medical sciences,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
April 1987, Cancer,
T Tanaka, and Y Kaneko, and F Haba, and S Katsuta, and K Tsutsui, and S Tamaki, and D R Chen, and S Suzuki, and R Ueda, and A Yamamoto
September 1989, Nihon Geka Gakkai zasshi,
Copied contents to your clipboard!